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ABSTRACT
Background: Positive results of randomized trials led to the introduction of FOLFIRINOX in 2012 and
gemcitabine with nab-paclitaxel in 2015 for patients with metastatic pancreatic ductal adenocarcin-
oma. It is unknown to which extent these new chemotherapeutic regimens have been implemented
in clinical practice and what the impact has been on overall survival.
Material and methods: Patients diagnosed with metastatic pancreatic ductal adenocarcinoma
between 2007–2016 were included from the population-based Netherlands Cancer Registry. Multilevel
logistic regression and Cox regression analyses, adjusting for patient, tumor, and hospital characteris-
tics, were used to analyze variation of chemotherapy use.
Results: In total, 8726 patients were included. The use of chemotherapy increased from 31% in
2007–2011 to 37% in 2012–2016 (p< .001). Variation in the use of any chemotherapy between centers
decreased (adjusted range 2007–2011: 12–67%, 2012–2016: 20–54%) whereas overall survival increased
from 5.6months to 6.4months (p< .001) for patients treated with chemotherapy. Use of FOLFIRINOX
and gemcitabine with nab-paclitaxel varied widely in 2015–2016, but both showed a more favorable
overall survival compared to gemcitabine monotherapy (median 8.0 vs. 7.0 vs. 3.8months, respect-
ively). In the period 2015–2016, FOLFIRINOX was used in 60%, gemcitabine with nab-paclitaxel in 9.7%
and gemcitabine monotherapy in 25% of patients receiving chemotherapy.
Conclusion: Nationwide variation in the use of chemotherapy decreased after the implementation of
FOLFIRINOX and gemcitabine with nab-paclitaxel. Still a considerable proportion of patients receives
gemcitabine monotherapy. Overall survival did improve, but not clinically relevant. These results
emphasize the need for a structured implementation of new chemotherapeutic regimens.
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Introduction
Most patients with pancreatic ductal adenocarcinoma (PDAC)
are diagnosed with metastatic disease [1–3]. These patients are
treated with palliative chemotherapy combined with support-
ive care or supportive care alone, depending on their perform-
ance status and preference. In 1997, gemcitabine was found to
improve survival compared to 5-fluorouracil (5.7 vs. 4.4months
median overall survival) [4]. Over the years, several combin-
ation chemotherapy regimens have been investigated without
any gain of survival [5,6]. More recently, FOLFIRINOX (5-fluo-
rouracil, leucovorin, irinotecan, and oxaliplatin) was associated
with a survival benefit compared to gemcitabine (11.1 vs.
6.8months median overall survival) in patients with a good
performance status [7]. The phase III MPACT trial revealed a
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superior survival with gemcitabine with nab-paclitaxel as com-
pared to gemcitabine alone (8.7 vs. 6.6months median overall
survival) [8]. It is unclear how these findings of trials with often
strict eligibility criteria translate to nationwide clinical practice.
Most population-based studies [1,9,10] on metastatic
PDAC were performed in the gemcitabine era. A recent study
in Canada [11] showed that use of FOLFIRINOX in patients
with metastatic PDAC increased from 41% in 2012 to 56% in
2014 although treatment regimens varied considerably
across geographic regions. In the Netherlands FOLFIRINOX
and gemcitabine with nab-paclitaxel were introduced in
2012 and 2015 respectively [7,8,11,12]. The identification of
nationwide trends over the years and variation across hospi-
tals is relevant as different treatment strategies might influ-
ence patients’ outcomes [7,8]. Patients could receive other
chemotherapy regimens leading to a difference in survival.
Nationwide variation between hospitals may exist over time,
due to geographical or hospital volume differences, but also
due to differences in patient characteristics and clinical prac-
tice in prescribing palliative chemotherapy [13–15]. For
example, physicians with less experience with triplet chemo-
therapy in the treatment of PDAC, may have been reluctant
to prescribe FOLFIRINOX treatment.
Therefore, the aim of this study is to assess whether the
implementation of new more effective chemotherapy regi-
mens (FOLFIRINOX and gemcitabine with nab-paclitaxel) for
patients with metastatic PDAC has affected nationwide clin-
ical practice and overall survival.
Methods
Data collection
For this nationwide study, data from the Netherlands Cancer
Registry (NCR) were used, covering the total population of
approximately 17 million inhabitants. Patients with a newly
diagnosed malignancy were identified by automatic notifica-
tions of the national pathological archive (PALGA) and the
National Hospital Discharge Register. Information on patient,
tumor and treatment characteristics, and visited hospitals (for
diagnosis and for treatment), were routinely collected from
medical records by trained NCR administrators. This study
was designed in accordance with the STROBE guidelines [16]
and the study protocol was approved by the scientific com-
mittee of the Dutch Pancreatic Cancer Group.
Study population
Patients diagnosed in the period 2007–2016 with PDAC
(International Classification of Disease – Oncology (ICD-O-3)
morphology code 8000, 8010, 8012, 8020, 8140, 8141, 8260,
8310, 8440, 8453, 8480, 8481, 8490, 8500 and 8560) and dis-
tant metastasis at time of diagnosis were extracted from the
NCR database. Patients younger than 18 years at diagnosis,
patients who underwent pancreatic resection, patients who
received neoadjuvant chemotherapy prior to surgical explor-
ation or patients who died within 30 days after diagnosis
were excluded.
For patients with metastatic PDAC, use of FOLFIRINOX was
recommended in 2012 and gemcitabine with nab-paclitaxel in
2015, after positive judgement of a national commission
(Commissie BOM). Therefore, the period of diagnosis was div-
ided into a period before (2007–2011) and after (2012–2016)
the implementation of the new regimens. Patients were
assigned as receiving chemotherapy treatment if they started
any chemotherapy regimen. Socioeconomic status (SES) was
based on social deprivation scores per 4-digit postal code (refer-
ence data from The Netherlands Institute of Social Research)
and categorized into three SES groups (high: 1st–3rd, intermedi-
ate 4th–7th, low: 8th–10th deciles). Primary tumor location was
classified as pancreatic head (C25.0), body (C25.1), tail (C25.2), or
other (C25.3, 7–9), according to the ICD-O-3. Metastatic organ
site(s) was categorized as liver only, peritoneum only, lung only,
extra-regional lymph nodes only, other site only, 2 sites (any
combination), 3 sites (any combination) and unknown.
Nationwide data on comorbid conditions, performance status
(WHO; Karnofsky scores were converted to WHO according to
the following values [17]: 90–100 to WHO 0, 80–90 to WHO 1,
60–70 to WHO 2, 40–50 to WHO 3, 20–30 to WHO 4) and type
of first-line chemotherapy were available for diagnoses in 2015
and 2016 only. Survival data were obtained by annual linkage
with the Municipal Personal Records Database, which contains
vital status of all Dutch inhabitants. Survival time was defined as
the time between the date of diagnosis and date of death or
censoring (1 February 2018).
Hospital classifications
Patients were assigned to their hospital of diagnosis, which
was defined as the hospital of first visit or clinical diagnosis
of PDAC. In 2016, patients were diagnosed in 78 hospitals in
the Netherlands, merged hospitals were counted as one for
the entire study period. Classifications of hospitals were: (1)
type of hospital, divided in university and non-university hos-
pitals; (2) volume of diagnoses of metastatic PDAC per hos-
pital per year, evenly divided into three groups (tertiles:
1–12, 13–19, 20–39); (3) volume of patients receiving chemo-
therapy per hospital per year (the number of patients with
metastatic PDAC with chemotherapy per hospital per year
was applied to all patients diagnosed with metastatic PDAC
in that hospital) (tertiles: 0–3, 4–6, 7–31); or (4) diagnosed in
a center for pancreatic surgery (no/yes, only available for
2012–2016). Nationwide variation for type of chemotherapy
could only be assessed for 2015–2016, because type of
chemotherapy was not registered before. In the analysis
about type of chemotherapy per hospital in 2015–2016, type
of chemotherapy was linked to the hospital of treatment.
Statistical analysis
Time trends in the use of chemotherapy and referral for
chemotherapy (chemotherapy treatment in other hospital than
hospital of diagnosis) were analyzed with the Chi-square for
trend. Multilevel logistic regression models were built to ana-
lyze variation of chemotherapy treatment between hospitals,
since patients were arranged in a natural hierarchy (clustered
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within hospitals) [18]. For each hospital of diagnosis (separately
for 2007–2011 and 2012–2016), a mean probability of receiving
chemotherapy was calculated, adjusted for differences in
patient and tumor characteristics. Change in hospital variation
between both time periods was investigated using intraclass
correlation coefficients (ICC) for the proportion of variance
explained by hospital level. Sensitivity analyses were performed
for patients (1) under 75 years only, (2) alive 60days after diag-
nosis, (3) with pathologically verified PDAC, and (4) diagnosed
in 2015–2016 additionally adjusted for number of comorbid
conditions and WHO performance status. To investigate mech-
anisms underlying the variation of receiving chemotherapy
between hospitals, the hospital classifications were added one
by one to the multivariable multilevel models.
Overall survival was analyzed by means of Kaplan–Meier
curves and compared with log-rank tests. Multivariable Cox
regression analyses were performed to assess the effect of
(1) the period of diagnosis (for all patients and for patients
receiving chemotherapy), (2) probabilities of receiving
chemotherapy per hospital grouped in tertiles (2007–2011
and 2012–2016 separately) and (3) the different chemother-
apy regimens (patients with chemotherapy in 2015–2016) on
survival. Results were presented as hazard ratios (HR) with a
95% confidence interval (CI). All multivariable regression
analyses were adjusted for sex, age, SES, pathological con-
firmation, primary tumor location, and number and location
of distant metastases. The third regression assessing the dif-
ferent chemotherapy regimens was also adjusted for per-
formance status and number of comorbidities. All p-values
were based on a 2-sided test and p-values of <.05 were con-
sidered statistically significant. Data was analyzed using IBM
SPSS Statistics for Windows version 24.0 (IBM Corp., Armong,
N.Y., USA) and Stata version 14.2 (StataCorp, TX, USA) for
multilevel analyses of hospital variation, performed by LvdG
to maintain anonymity of hospitals.
Results
Patient population
In total, 8726 patients diagnosed with metastatic PDAC were
included. The median age was 68 years (range 21–99) and
one-third of patients was treated with chemotherapy (34%).
Table 1 provides an overview of the baseline characteristics.
Use of palliative chemotherapy increased significantly from
31% in 2007–2011 to 37% in 2012–2016 (p< .001, Figure
1(A)). During 2012–2016, the use of chemotherapy stabilized
(p-trend¼ .20). The percentage of patients that was referred
to another hospital for chemotherapy treatment decreased
from 22% to 10% from 2007–2011 (p-trend¼ .001) and fluc-
tuated between 13% and 18% in 2012–2016 (p-trend¼ .23).
Median age of patients receiving chemotherapy was 63 and
64 years in the consecutive time periods.
Nationwide variation in administration of chemotherapy
In the study period, an increasing number of hospitals pro-
vided chemotherapy to patients diagnosed with metastatic

















Male 4496 (52%) 2033 (52) 33% .002 2463 (51) 39% <.001
Female 4230 (48) 1908 (48) 29% 2322 (49) 34%
Age (years) <.001 <.001
<50 413 (5%) 207 (5) 52% 206 (4) 67%
50–59 1427 (16%) 683 (17) 46% 744 (16) 57%
60–69 2857 (33%) 1294 (33) 41% 1563 (33) 47%
70–79 2832 (32%) 1229 (31) 21% 1603 (36) 27%
80 1197 (14%) 528 (13) 4% 669 (14) 4%
Socioeconomic status .017 .016
High 2619 (30) 1207 (31) 32% 1412 (30) 39%
Medium 3490 (40) 1552 (39) 33% 1938 (41) 37%
Low 2617 (30) 1182 (30) 28% 1435 (30) 34%
Pathologically confirmed <.001 <.001
Yes 6430 (74%) 2814 (71) 39% 3616 (76) 45%
No 2296 (26) 1127 (29) 13% 1169 (24) 12%
Primary tumor location <.001 <.001
Head of pancreas 4121 (47%) 1971 (50) 28% 2150 (45) 33%
Body of pancreas 1317 (15%) 552 (14) 36% 765 (16) 43%
Tail of pancreas 1874 (21%) 784 (20) 38% 1090 (23) 40%
Other 1414 (16%) 634 (16) 30% 780 (16) 37%
Metastatic site <.001 .114
Liver 4384 (50%) 2098 (53) 32% 2286 (48) 36%
Lung 401 (5%) 187 (5) 21% 214 (5) 33%
Peritoneum 746 (9%) 306 (8) 26% 440 (9) 39%
Extra regional lymph nodes 317 (4%) 143 (4) 29% 174 (4) 41%
Other 195 (2%) 88 (2) 18% 107 (20 26%
2 Metastatic sitesa 1920 (22%) 812 (21) 33% 1108 (23) 38%
3 or more metastatic sitesa 730 (8%) 275 (7) 37% 455 (10) 36%
Unknown 33 (<1%) 32 (1) 22% 1 (<1) –
Bold numbers indicate statistical significance.
aAny combination of metastatic sites.
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PDAC: 60 (IQR 58–67) hospitals per year in the period
2007–2011 and 71 (IQR 70–72) hospitals in the period
2012–2016 (p¼ .009). The median number of patients receiv-
ing chemotherapy per treating hospital was 13 and 21
patients per five-year period, respectively.
Between individual hospitals of diagnosis, a large variation
in chemotherapy prescription for patients with metastatic pan-
creatic cancer was found (observed range in 2007–2011:
6.3–87%, 2012–2016: 14–62%). Multilevel analyses, adjusted
for patient and tumor characteristics, showed that this vari-
ation decreased over time (adjusted probabilities ranges:
12–67% and 20–54%, and ICC: 14% and 6%, respectively,
Supplementary Figure 1). Sensitivity analyses showed similar
ranges between hospitals (Supplementary Table 1). In hospi-
tals with high volumes of chemotherapy and in hospitals with
high volumes of diagnoses, the likelihood of receiving chemo-
therapy was significantly higher (respectively, compared to
medium and low volumes in both time periods and compared
to low volumes in 2007–2011 only, Table 2). Being diagnosed
in a university hospital or a center for pancreatic surgery was
not associated with the likelihood of receiving chemotherapy.
Overall survival
Patients who received chemotherapy had a median overall
survival of 6.0months (95%CI 5.8–6.2) compared to
2.5months (95%CI 2.4–2.6) in patients without chemotherapy
use (p< .001). In all patients, median overall survival slightly
improved between 2007–2011 and 2012–2016 (3.3 vs.
3.4months, p< .001) with a 1-year survival of 7.6% vs. 9.6%
respectively (Table 3, Figure 1(B)). After adjustment for
patient and tumor characteristics, patients in 2012–2016 had
a significantly higher overall survival compared with patients
in 2007–2011 in multivariable Cox regression (adjusted HR
0.91, 95%CI 0.87–0.95, p< .001). Besides increased chemo-
therapy use, patients treated with chemotherapy in
2012–2016 also had slightly better median overall survival
(6.4months vs. 5.6months, p< .001) and 1-year overall sur-
vival (20% vs. 15%) than in 2007–2011 (adjusted HR 0.82,
95%CI 0.76–0.89). Median overall survival did not increase
sequentially per year (6.5–6.2–6.4–6.3–6.7months in
2012–2013–2014–2015–2016).
In 2007–2011, patients diagnosed in hospitals with low
and intermediate probabilities of receiving chemotherapy
Figure 1. Use of chemotherapy in and survival of all patients with metastatic pancreatic ductal adenocarcinoma in 2007–2016. (A) Use of chemotherapy in patients
with metastatic pancreatic ductal adenocarcinoma and the percentage of patients that were referred for chemotherapy treatment in 2007–2011 and 2012–2016 in
the Netherlands. (B) Median overall survival and 1-year survival of all patients with metastatic pancreatic ductal adenocarcinoma in 2007–2016.
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had a significant lower overall survival compared to patients
in hospitals with high probabilities (adjusted HR 1.21, 95%CI
1.12–1.31 and 1.12, 95%CI 1.03–1.20, respectively, Table 3). In
2012–2016, a significant worse survival was only found in
patients diagnosed in hospitals with a low probability of
receiving chemotherapy treatment compared to a high prob-
ability (adjusted HR 1.13, 95%CI 1.05–1.21, Table 3).
Nationwide variation in type of chemotherapy
In 2015–2016, 36% of all patients (723 patients) received
chemotherapy of whom most patients received the newly
introduced regimens: 436 patients FOLFIRINOX (60%) and 70
patients gemcitabine plus nab-paclitaxel (9.7%, Supplementary
Table 2). The remaining patients received gemcitabine only
(182 patients, 25%), and other or unknown chemotherapy
regimens (35 patients, 4.8%). FOLFIRINOX was given in nearly
all hospitals (72/74 hospitals of treatment in 2015–2016), while
less than one-third of hospitals administered gemcitabine plus
nab-paclitaxel (22/74, Figure 2). Gemcitabine monotherapy
was administered to a relatively low proportion of patients in
university hospitals. In general, patients treated with
FOLFIRINOX were younger (median 61 vs. 66–70years) and
had a better performance score compared to patients treated
with other regimens (WHO 0–1 in 70% vs. 44–69%).
Compared to patients treated with gemcitabine, patients
receiving FOLFIRINOX and gemcitabine plus nab-paclitaxel
had a significantly higher median OS (3.8months vs.
8.0months vs. 7.0months respectively). In multivariable Cox
regression the corresponding adjusted HR were 0.46 (95%CI
0.37–0.57, p< .001) and 0.46 (95%CI 0.34–0.63, p< .001),
respectively, compared to gemcitabine only.
Table 2. Proportion of patients receiving chemotherapy and multivariable multilevel logistic regression to investigate hospital-related predictors for chemother-
apy use in patients diagnosed with metastatic pancreatic ductal adenocarcinoma in the Netherlands in 2007–2016, for 2 periods of diagnosis separately.
Period 2007–2011 Period 2012–2016
Hospital measuresa
% of patients with
chemotherapy p-value OR (95% CI) p-value
% of patients with
chemotherapy p-value OR (95% CI) p-value
Classification 1
Type of hospital .858 .236
University 31.5 1.00 (reference) 33.7 1.00 (reference)
Non-university 31.1 1.66 (0.93–2.99) .088 37.0 1.48 (0.98–2.24) .065
Classification 2
Hospital volume of diagnoses .057 .467
High 32.2 1.00 (reference) 37.0 1.00 (reference)
Medium 33.0 0.86 (0.66–1.12) .260 35.5 0.89 (0.72–1.12) .322
Low 29.1 0.66 (0.49–0.89) .006 37.6 0.96 (0.77–1.21) .761
Classification 3
Hospital volume of chemotherapy <.001 <.001
High 47.9 1.00 (reference) 44.5 1.00 (reference)
Medium 38.0 0.62 (0.47–0.80) <.001 38.0 0.76 (0.64–0.91) .003
Low 19.9 0.24 (0.19–0.31) <.001 25.3 0.37 (0.30–0.46) <.001
Classification 4 Not applicable
Pancreatic center (surgery) .104 .052
No 37.5 1.00 (reference)
Yes 34.9 0.77 (0.59–1.00)
Bold numbers indicate statistical significance.
P: percentage of patients receiving chemotherapy; OR: odds ratio; CI: confidence interval.
aIndividual hospital classifications were adjusted for sex, age, SES, pathological confirmation, location of primary tumor, number and location of distant metasta-
ses, and hospital of diagnosis by using multilevel regression analysis.
Table 3. Univariable and multivariable Cox regression analyses of overall survival for all patients with metastatic pancreatic ductal adeno-
carcinoma in the Netherlands in 2007–2016, overall and for 2 periods of diagnosis separately.
Univariable Multivariablea
N ¼ Crude 1-year OS (%) HR (95% CI) HR (95% CI) p-value
All patients
Period
2007–2011 3941 7.6 1.00 (reference) 1.00 (reference)
2012–2016 4785 9.6 0.92 (0.88–0.96) 0.91 (0.87–0.95) <.001
Period 2007–2011
Chemotherapy treatment probabilityb
High (36%–67%) 1275 9.4 1.00 (reference) 1.00 (reference)
Medium (25%–35%) 1344 7.9 1.13 (1.04–1.22) 1.12 (1.03–1.20) <.001
Low (12%–25%) 1322 5.7 1.22 (1.13–1.32) 1.21 (1.12–1.31) .006
Period 2012–2016
Chemotherapy treatment probabilityb
High (40%–54%) 1543 11.4 1.00 (reference) 1.00 (reference)
Medium (35%–39%) 1571 9.4 1.09 (1.01–1.17) 1.05 (0.98–1.13) .202
Low (20%–34%) 1671 8.2 1.19 (1.11–1.28) 1.13 (1.05–1.21) .001
Bold numbers indicate statistical significance.
aAdjusted for sex, age, SES, pathological confirmation, location of primary tumor, number and location of distant metastases.
bWithin periods of diagnosis patients were evenly divided into three groups according to the adjusted probabilities of receiving chemo-
therapy (per hospital per period) based on the hospital of diagnosis.
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Discussion
This population-based analysis of patients with metastatic
PDAC showed that over the course of a decade the nation-
wide use of chemotherapy increased and the nationwide
variation in the use of chemotherapy decreased. Since the
introduction of FOLFIRINOX and gemcitabine with nab-pacli-
taxel the overall survival of all patients with metastatic dis-
ease increased slightly, yet significantly (from 0.1 to
0.8months) although only one third of patients received
chemotherapy. FOLFIRINOX was widely implemented in
2015–2016, but its use varied between hospitals. A consider-
able proportion of patients still received gemcitabine mono-
therapy. Nevertheless, differences in survival due to variation
in use of chemotherapy between hospitals seem to have
decreased over the study period.
During the last decade, on average 34% of patients with
metastatic PDAC received chemotherapy in the Netherlands
compared to 17–58% [9,10,15,19–22] reported from other
countries. Between 2007–2011 and 2012–2016, an increase
was observed in the use of chemotherapy. The volume of
patients receiving chemotherapy per hospital increased,
more hospitals prescribed chemotherapy and consequently
the number of referrals to tertiary centers decreased.
Moreover, variation between hospitals in the probability of
receiving chemotherapy for metastatic PDAC per hospital
decreased in 2012–2016. Hospitals with a higher volume of
patients receiving chemotherapy had an increased likelihood
of receiving chemotherapy in both 2007–2011 and
2012–2016. Hospital volume of diagnosis did affect the likeli-
hood of receiving chemotherapy in 2007–2011, but this
effect disappeared in 2012–2016. Type of hospital or pancre-
atic surgery centers did not affect the likelihood of receiving
chemotherapy in both periods. There are several possible
explanations for the increased use of chemotherapy
(regardless of the type of chemotherapy) and the decrease
in variation between hospitals: 1) the introduction of
FOLFIRINOX and gemcitabine with nab-paclitaxel with
reported higher survival benefits; 2) the rise of inter-hospital
multidisciplinary meetings; and 3) the implementation of the
national guideline on PDAC in 2011 [7,8,23].
On a population level, results of the new chemotherapy
regimens on overall survival are somewhat disappointing. As
expected, in patients receiving chemotherapy the survival
increase was higher compared to patients who did not receive
chemotherapy, but still only 0.8months (24 days). The overall
survival of patients treated with FOLFIRINOX was lower than
in the randomized controlled trial (8.0months in our study vs.
11.1months in the trial of Conroy et al. [7]). This was also the
case for gemcitabine with nab-paclitaxel (7.0 in our study vs.
8.7months in the trial of Goldstein et al. [8]). The limited
effect on survival on population level probably originates from
differences in patient selection compared to clinical trials.
Another study [24] including patients with advanced pancre-
atic cancer from a single institution showed that survival
could achieve benefits as shown in randomized clinical trials,
but that this differed between treatment regimens. Moreover,
the study demonstrated protocol adherence to be one of the
explanations for differences between real-world outcomes and
results in randomized controlled trials. Both the effects of
patient selection and protocol adherence emphasize the
importance of population-based studies to show real-life
effects of new treatments [25].
Remarkably, gemcitabine was still often prescribed (25%).
The median overall survival of patients receiving this regi-
men was considerably low (3.8months) compared to the
new chemotherapy regimens (FOLFIRINOX and gemcitabine
plus nab-paclitaxel 8.0 and 7.0months, respectively) and to
patients without chemotherapy use (2.5months). This could
Figure 2. Proportions of type of chemotherapy per hospital of treatment for patients diagnosed with metastatic pancreatic ductal adenocarcinoma in 2015–2016,
N¼ 74/78 hospitals prescribed chemotherapy. The number of patients receiving chemotherapy per 2 years was grouped and represented in the figure. The asterisk
represents a university hospital.
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be related to worse performance status in these patients. A
population-based study from the United States [13] found a
rapid decline of the use of gemcitabine monotherapy after
2009. Gemcitabine can be considered currently in patients
not eligible for FOLFIRINOX or gemcitabine with nab-
paclitaxel. In daily practice these are patients with multiple
comorbidities, a WHO performance status of 2, or patients
older than 75 years, because those patients were not
included in the previously mentioned trial [7]. In our cohort,
gemcitabine was not only prescribed in this selected popula-
tion, but it was also given to patients younger than 70 years
old, with a WHO performance score of 0, and without comor-
bidities. Probably the relatively severe toxicity of these new
regimens, and the inexperience with the chemotherapy com-
binations restrain the medical oncologist in prescribing these
drugs [26].
Based on the results, speculations for future perspectives
could be made. Better outcomes on population level and a
decrease of variation might be achieved by further imple-
mentation of the new chemotherapy regimens. Enhanced
implementation of new treatments should be performed on
a national scale by a structured approach. It could be consid-
ered to centralize (palliative) care of PDAC, because in
2012–2016 there still was a difference in the probability of
receiving chemotherapy between centers (however less pro-
nounced compared to 2007–2011). Also, type of chemother-
apy prescribed was highly variable between hospitals. In
pancreatic surgery, centralization increased resection rates
and reduced mortality [27,28]. In palliative care there is lim-
ited data on the benefit of centralization, or at least central-
ized assessment, but it has been demonstrated that volume
matters regarding the use of chemotherapy [15].
This study has some limitations. First, the incidence of
PDAC is underestimated in the NCR. The missing patient
group consists especially of elderly patients without patho-
logical confirmation of cancer, patients with no cancer treat-
ment and patients with a very poor survival [29]. To reduce
the influence of possible incompleteness, only patients alive
at 30 days after diagnosis were included. Sensitivity analyses
addressing these limitations (selecting younger patients,
pathologically confirmed PDAC or patients alive at 60 days
after diagnosis) showed similar patterns. Second, treatment
allocation bias could have occurred. To reduce this bias,
patients who died within 30 days after diagnosis were
excluded. Third, important case-mix factors like comorbid
conditions and performance status were not available in the
total study period. However, a similar pattern was found in
sensitivity analysis including these factors. Fourth, details
about chemotherapy regimens were only available for the
2015–2016 period. Possible trends in the use of FOLFIRINOX
and nab-paclitaxel with gemcitabine could not be confirmed.
In conclusion, nationwide variation in the use of chemo-
therapy in patients with metastatic PDAC decreased after the
implementation of FOLFIRINOX and gemcitabine with nab-
paclitaxel in 2012–2016. Nevertheless, a considerable propor-
tion of patients still received gemcitabine with a disappoint-
ing survival benefit. This study clearly shows that the
implementation of more effective chemotherapeutic
regimens in patients with metastatic PDAC is difficult and
does not translate directly to a clinically relevant improve-
ment in overall survival. These results emphasize the need
for a structured implementation of new and more effective
chemotherapeutic regimens in order to increase the use of
these regimens and further decrease prescription variations.
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